Statins, ezetimibe, bile acid sequestrants, and more recently PCSK9 inhibitors are the main therapeutic drugs for the treatment of heterozygous FH (HeFH); all of which work solely or predominantly via increased LDLR activity and LDL-C clearance. This evidence concerns the gene LDLR and familial hyperaldosteronism.